<DOC>
	<DOCNO>NCT02780882</DOCNO>
	<brief_summary>The purpose prospective open-label phase II study , evaluate efficacy pasireotide twice daily subcutaneous injection normalize 24 hour urine free cortisol patient ectopic ACTH-producing tumor measure proportion patient achieve normal UFC end study period .</brief_summary>
	<brief_title>SOM230 Ectopic ACTH-producing Tumors</brief_title>
	<detailed_description />
	<mesh_term>Cardiac Complexes , Premature</mesh_term>
	<mesh_term>ACTH Syndrome , Ectopic</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<criteria>Written inform consent obtain prior screen procedure Male female patient age 18 year great Confirmed nonpituitary ectopicACTH secrete tumor Well differentiate , low intermediate grade ( WHO classification G12 ) neuroendocrine tumor Tumor size increase &lt; 10 % 6 month prior screen CT MRI Mean 24hour urinary free cortisol level least 1.5 x upper limit normal range , morning plasma ACTH level &gt; 5 ng/L Patients highly malignant ACTHsecreting tumor , i.e . smallcell lung carcinoma , medullary thyroid carcinoma , pheochromocytoma Patients poorly differentiate neuroendocrine tumor ( WHO classification G3 ) Patients &gt; 10 % increase tumor size 6 month prior screen CT MRI Patients Cushing 's syndrome due pituitary ACTH secretion Patients hypercortisolism secondary adrenal tumor nodular ( primary ) bilateral adrenal hyperplasia Patients know inherited syndrome cause hormone secretion ( i.e . Carney Complex , McCuneAlbright syndrome , MEN1 ) Patients diagnosis glucocorticoidremedial aldosteronism ( GRA ) Patients undergone major surgery within 1 month prior screen Patients know gallbladder bile duct disease , acute chronic pancreatitis ( patient asymptomatic cholelithiasis asymptomatic bile duct dilation include ) Diabetic patient whose blood glucose poorly control evidence HbA1C &gt; 8 % Patients clinically significant impairment cardiovascular function risk thereof , evidence Congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , clinically significant bradycardia , high grade AV block , history acute MI le one year prior study entry QTcF &gt; 450 msec screen History syncope family history idiopathic sudden death Risk factor Torsades de Pointes uncorrected hypokalemia , uncorrected hypomagnesemia , cardiac failure Concomitant disease ( ) could prolong QT interval autonomic neuropathy ( cause diabetes Parkinson 's disease ) , HIV , cirrhosis , uncontrolled hypothyroidism , concomitant medication ( ) know increase QT interval Patients liver disease history liver disease cirrhosis , chronic active hepatitis B C , chronic persistent hepatitis , patient ALT AST 2 x ULN , serum creatinine &gt; 2.0 x ULN , serum bilirubin &gt; 1.5 x ULN , serum albumin &lt; 0.67 x LLN screen Patients ongoing plan antineoplastic therapy Has treat radionuclide time prior study entry Is likely require additional concomitant treatment pasireotide tumor Patients current prior medical condition interfere conduct study evaluation result , History immunocompromise , include positive HIV test result ( Elisa Western blot ) . An HIV test require , however , previous medical history review Presence active suspect acute chronic uncontrolled infection History , current alcohol misuse/abuse 12 month period prior screen Female patient pregnant lactating , childbearing potential practicing medically acceptable method birth control . If woman participate trial one form contraception sufficient ( pill diaphragm ) partner use condom . If oral contraception use addition condom , patient must practice method least two month prior screen must agree continue oral contraceptive throughout course study 3 month study end . Male patient sexually active require use condom study three month afterwards precautionary measure ( available data suggest increase reproductive risk study drug ) Patients participate clinical investigation investigational drug within 1 month prior screen patient previously treat pasireotide Known hypersensitivity somatostatin analogues Patients history noncompliance medical regimen consider potentially unreliable unable complete entire study Patients presence Hepatitis B surface antigen ( HbsAg ) Patients presence Hepatitis C antibody test ( antiHCV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Pasireotide</keyword>
	<keyword>Ectopic ACTH</keyword>
	<keyword>SOM230</keyword>
	<keyword>ectopic ACTH-dependent Cushing 's syndrome</keyword>
</DOC>